In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mark Ratner

Latest From Mark Ratner

Understanding How To Develop BTK Inhibitors In MS Is Evolving

Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.

Clinical Trials Drug Safety

Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development

Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.

Digital Health Cancer

Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development

Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.

Digital Health Cancer

Harbingers For IPF Drug Development

Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.

Respiratory Market Intelligence

Pharma’s Digital Pathology Build-Out; Part 2 – What It Means

Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.

Diagnostics Artificial Intelligence

Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play

Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?

Artificial Intelligence Diagnostic Imaging
See All
UsernamePublicRestriction

Register